In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.
All content for Mcgill University Medical Podcast Series is the property of Mcgill University Medical Podcast Series and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.
Episode 2 - Devin Abrahami - DPP-4 inhibitors and incidence of IBD among patients with DMII
Mcgill University Medical Podcast Series
25 minutes 24 seconds
7 years ago
Episode 2 - Devin Abrahami - DPP-4 inhibitors and incidence of IBD among patients with DMII
On this episode we're very grateful to have interviewed PhD candidate Devin Abrahami, the first author of the paper "Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study" published in the March 2018 issue of the British Medical Journal. This paper from the group of Dr. Laurent Azoulay really made a lot of waves in the medical community, achieving an Altmetric score of 320 and still climbing and is a must-read.
Mcgill University Medical Podcast Series
In this episode, we're joined by Dr. Richard Menzies and Dr. Jonathan Campbell from the McGill Respiratory Epidemiology and Clinical Research Unit to discuss the results of their multi-center RCT comparing 4 months of rifampin to 9 months of isoniazid for the treatment of latent TB. Their findings are outlined in two papers, entitled "Four Months of Rifampin or Nine Months of Isoniazid for Latent TB in Adults" and "Safety and Side Effects of Rifampin Versus Isoniazid in Children" published in the August 2018 issue of the New England Journal of Medicine.
